

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Transplantation*

**Manuscript NO:** 68271

**Title:** Tolerance protocol of living kidney transplant for developing countries through basic strategy of lymphocyte depletion

**Provenance and peer review:** Invited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 02524651

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Professor

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** Singapore

**Manuscript submission date:** 2021-05-17

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-05-25 04:21

**Reviewer performed review:** 2021-05-30 01:56

**Review time:** 4 Days and 21 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input checked="" type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No

<b>Peer-reviewer statements</b>	Peer-Review: [ <input checked="" type="checkbox"/> ] Anonymous [ <input type="checkbox"/> ] Onymous Conflicts-of-Interest: [ <input type="checkbox"/> ] Yes [ <input checked="" type="checkbox"/> ] No
-------------------------------------	---

## SPECIFIC COMMENTS TO AUTHORS

The opinion review "Tolerance Protocol of Living Kidney Transplant For Developing Countries Through Basic Strategy of Lymphocyte Depletion" suggest a stagey to induce Partial or Prope tolerance in LKT recipients: giving R-CHOP chemotherapy prior to transplantation. The opinion is interesting. 1, Although the protocols of MGH, Stanford and Northwestern include rituximab, high dose CTX and other potent lymphocyte deletion treatments, tolerance still failed in part of recipients. Considering the authors have only 1 case experience in PTLT patient, the effects of R-CHOP chemotherapy on tolerance need more data to have conclusion. In fact, many PTLT recipients have received R-CHOP chemotherapy. After cure, they still need receive maintenance immunosuppressive therapy to avoid rejection. 2, The authors suggest "Target neutrophil and lymphocyte counts are  $1 \times 10^9/L$  and  $0.5 \times 10^9/L$ ". How to evaluate the risk of infection and the safety? 3, Does the status of "a half dose dual immunosuppressive therapy" mean "Partial or Prope tolerance"? How to test the status of "Partial or Prope tolerance"? 4, A stagey to induce Partial or Prope tolerance will benefit the recipient world-wide. I don't think it is necessary to focus on developing Countries. 5, The abstract gives too much background introduction. Should focus on the authors' strategy.

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Transplantation*

**Manuscript NO:** 68271

**Title:** Tolerance protocol of living kidney transplant for developing countries through basic strategy of lymphocyte depletion

**Provenance and peer review:** Invited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 03945842

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Doctor

**Reviewer's Country/Territory:** Italy

**Author's Country/Territory:** Singapore

**Manuscript submission date:** 2021-05-17

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-05-26 10:46

**Reviewer performed review:** 2021-05-30 18:37

**Review time:** 4 Days and 7 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

<b>Peer-reviewer statements</b>	Peer-Review: [ <input checked="" type="radio"/> ] Anonymous [ <input type="radio"/> ] Onymous Conflicts-of-Interest: [ <input type="radio"/> ] Yes [ <input checked="" type="radio"/> ] No
-------------------------------------	---

#### **SPECIFIC COMMENTS TO AUTHORS**

Thank you for the opportunity to revise this manuscript. The author explores an interesting field of transplantation and hypothesizes the implementation of a new immunosuppressive regimen protocol able to reduce the post-transplant need of immunosuppressive drugs. These results may be helpful for Developing Countries in order to reduce costs and for synplify post-transplant management. However I experience the need of a section that clarifies the hypothetical worsening effects in terms of post-transplant infections and neoplasms and also the risks for patients that will experience PNF.

## RE-REVIEW REPORT OF REVISED MANUSCRIPT

**Name of journal:** *World Journal of Transplantation*

**Manuscript NO:** 68271

**Title:** Tolerance protocol of living kidney transplant for developing countries through basic strategy of lymphocyte depletion

**Provenance and peer review:** Invited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 02524651

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Professor

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** Singapore

**Manuscript submission date:** 2021-05-17

**Reviewer chosen by:** Jia-Ping Yan

**Reviewer accepted review:** 2021-07-30 02:26

**Reviewer performed review:** 2021-07-31 03:31

**Review time:** 1 Day and 1 Hour

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Peer-reviewer</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
<https://www.wjgnet.com>

statements

Conflicts-of-Interest: [ ] Yes [Y] No

#### **SPECIFIC COMMENTS TO AUTHORS**

The quality of the revised version is improved.